The Gut-Brain Axis in Parkinson's, Long COVID, and Neurological Disease: Where the Research Stands

For decades, neurological diseases like Parkinson's were studied almost entirely from the neck up. The brain was degenerating, so the answers had to be in the brain. That framing has started to shift. Researchers have found the molecular hallmarks of Parkinson's disease in the gut years before they appear in the brain. Epidemiological data shows that people who had their vagus nerve surgically cut have lower Parkinson's risk. And in long COVID, persistent GI symptoms and autonomic dysfunction point to a gut-brain connection that may explain part of why the disease lingers. None of this means the gut causes these diseases in any simple sense. But the evidence that the gut is involved, and involved early, is now strong enough that mainstream neuroscience takes it seriously. This article covers what the research actually shows, where the boundaries of current knowledge are, and why the gap between 'the gut is involved' and 'we can fix it through the gut' is still substantial.

The Braak hypothesis: does Parkinson's start in the gut?

In 2003, neuroanatomist Heiko Braak proposed a staging system for Parkinson's disease that placed the earliest pathological changes not in the substantia nigra (the brain region whose degeneration causes the classic motor symptoms) but in the olfactory bulb and the enteric nervous system (Braak et al., 2003). His hypothesis was that alpha-synuclein, the protein that misfolds and aggregates in Parkinson's, might enter the body through the nose or the gut and spread to the brain via nerve fibers, specifically the vagus nerve connecting the gut to the brainstem. When Braak first proposed this, it was considered provocative. The evidence was anatomical: post-mortem studies showing alpha-synuclein pathology in a pattern that could be interpreted as ascending from the periphery.

Since then, the evidence has accumulated. Shannon et al. (2012) found alpha-synuclein aggregates in colonic biopsies from Parkinson's patients and even from some individuals who had not yet developed motor symptoms. Svensson et al. (2015) published a large Danish registry study showing that people who had undergone a full truncal vagotomy (complete surgical cutting of the vagus nerve trunk) had a significantly lower risk of developing Parkinson's over the following 20 years compared to the general population. The effect was not seen in people who had a selective vagotomy (where only some branches were cut), which is consistent with the idea that an intact vagus nerve provides a route for pathological spread from the gut to the brain.

2025 Stanford research: alpha-synuclein spreading from gut to brain

A 2025 study from Stanford, led by Kim et al., provided some of the most direct experimental evidence for gut-to-brain alpha-synuclein spread. The researchers injected misfolded alpha-synuclein into the gut wall of mice and tracked its spread over time. They observed that the pathological protein traveled along the vagus nerve to the dorsal motor nucleus in the brainstem, and from there progressed to higher brain regions in a pattern that recapitulated Braak staging in humans. Mice that had undergone vagotomy before the injection did not develop brain pathology, confirming that the vagus nerve was the route of spread. The mice also developed motor deficits and GI dysfunction that mirrored aspects of human Parkinson's disease.

This study built on earlier work by other groups but used improved techniques for tracking the protein spread in real time and for confirming that the spreading alpha-synuclein was pathologically active (capable of seeding further aggregation) rather than inert. It does not prove that this is how Parkinson's starts in most humans. The injection of concentrated misfolded protein into the gut is a very different scenario from whatever initiates the disease naturally. But it demonstrates that the mechanism is biologically possible: the gut-to-brain route via the vagus nerve works in a living system, and the resulting brain pathology looks like Parkinson's disease.

Constipation as an early warning sign

One of the most consistent epidemiological findings in Parkinson's research is that constipation precedes the onset of motor symptoms by many years. A meta-analysis by Adams-Carr et al. (2016) found that individuals with constipation had a significantly elevated risk of developing Parkinson's disease over the following 10 to 20 years. This prodromal period, when GI symptoms are present but motor symptoms have not yet appeared, aligns with the Braak hypothesis: if alpha-synuclein pathology begins in the enteric nervous system before reaching the brain, you would expect gut dysfunction to appear first.

It is important to emphasize that constipation is extremely common in the general population and is not, by itself, a predictor of Parkinson's disease. Most people with constipation will never develop Parkinson's. The association becomes more clinically relevant when constipation appears alongside other prodromal features such as loss of smell (hyposmia), REM sleep behavior disorder (acting out dreams), depression, or anxiety. This cluster of prodromal symptoms is now an active area of research for early Parkinson's detection, and the GI component is a key piece of that puzzle.

Long COVID, vagal dysfunction, and the gut

Long COVID, defined as persistent symptoms lasting 12 weeks or more after SARS-CoV-2 infection, affects an estimated 10 to 30% of COVID-19 survivors. Among the many symptoms reported, GI complaints, including nausea, abdominal pain, diarrhea, and bloating, are common but often overshadowed by fatigue, brain fog, and cardiac symptoms. However, research has identified autonomic dysfunction as a significant feature of long COVID, and this dysfunction directly implicates the vagus nerve and the gut-brain axis.

Buoite Stella et al. (2022) found that long COVID patients had significantly reduced heart rate variability compared to recovered controls, indicating impaired vagal tone. Other studies have documented postural orthostatic tachycardia syndrome (POTS), a form of dysautonomia, in long COVID patients at rates far exceeding the general population. The mechanisms are not fully understood, but several hypotheses are under investigation. Direct viral injury to vagal neurons is possible, as ACE2 receptors (the entry point for SARS-CoV-2) are expressed on enteric neurons and vagal afferents. Autoimmune mechanisms, where the immune response to the virus produces antibodies that cross-react with autonomic receptors, have been proposed based on the finding of anti-ganglionic acetylcholine receptor antibodies in some long COVID patients. And persistent low-grade inflammation, driven by viral remnants in the gut (SARS-CoV-2 RNA has been detected in stool samples months after acute infection), could maintain vagal dysfunction without requiring ongoing active infection.

For the subset of long COVID patients with prominent GI symptoms, impaired vagal tone could explain many of their complaints. Reduced vagal motor function slows gastric emptying and impairs the migrating motor complex, leading to bloating, early fullness, and small intestinal bacterial overgrowth. Reduced vagal sensory function could impair the normal feedback loops between the gut and brain that regulate appetite, nausea, and bowel habits. While these connections are plausible and supported by emerging data, the long COVID field is still young, and definitive answers about mechanism and treatment are not yet available.

The microbiome connection in neurological disease

Studies consistently find that the gut microbiome of Parkinson's disease patients differs from healthy controls. Scheperjans et al. (2015) published one of the first large studies showing reduced abundance of Prevotellaceae and increased Enterobacteriaceae in Parkinson's patients, and numerous studies since have confirmed altered microbiome profiles in the disease. The pattern generally shows reduced production of short-chain fatty acids (due to loss of fiber-fermenting bacteria) and increased abundance of pro-inflammatory species.

The question is whether these microbiome changes drive the disease, result from the disease, or are a consequence of the medications Parkinson's patients take. Levodopa and other Parkinson's medications affect gut motility and pH, both of which shape microbiome composition. Constipation itself (a feature of the disease) alters transit time and therefore the microbial environment. Disentangling cause and effect is extremely difficult. Similar microbiome differences have been reported in Alzheimer's disease, multiple sclerosis, and ALS, but in all cases, the causal direction remains unclear.

What helps: being informed without being alarmed

The gut-brain axis research in neurological disease is at an early but genuinely promising stage. For most people reading this article, the practical implications are limited but real. If you have a family history of Parkinson's disease and you develop persistent constipation along with loss of smell or sleep disturbances, mentioning these symptoms to a neurologist is reasonable and may contribute to early monitoring if the disease does develop. For long COVID patients with GI symptoms, understanding that autonomic dysfunction may be a factor can help guide conversations with healthcare providers toward appropriate testing (tilt table testing for POTS, HRV monitoring) rather than dismissing symptoms as anxiety or post-illness adjustment.

For anyone dealing with persistent GI symptoms in the context of neurological concerns, tracking symptom patterns over time provides useful data for medical appointments. A tool like GLP1Gut can help document the timing, severity, and context of digestive symptoms, which is especially valuable when symptoms are intermittent and hard to describe from memory. Bringing a log of actual symptom data to an appointment is more useful than trying to summarize weeks of variable symptoms in a 15-minute visit.